ArticleChembiochem : a European journal of chemical biology2025
Cold-Adapted Lipid A from Polaribacter sp. SM1127: A Study of Structural Heterogeneity and Immunostimulatory Properties.
Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Concentrated Rhamnolipid Formulations: Bridging Chemodiversity to Structure, Flow Behavior, and Functionality.ACS sustainable chemistry & engineering · 2026Article
- Structural and Immunological Insights into the Lipooligosaccharide of the Marine BacteriumMarine drugs · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Polaribacter sp. SM1127, a cold-adapted marine Gram-negative bacterium isolated from Laminaria in Arctic waters, plays a crucial role in nutrient cycling and biopolymer degradation in cold environments. Additionally, its exopolysaccharide (EPS) exhibits promising biotechnological potential, including antioxidant and wound-healing properties. This study focuses on the isolation and characterization of lipid A, the glycolipid component of Polaribacter sp. SM1127 lipopolysaccharide (LPS), by bypassing full LPS extraction and working directly with the ethanol precipitation product containing both EPS and bacterial cells. Mass spectrometry analysis reveals significant structural heterogeneity in the lipid A, with variations in fatty acid chain length, branching, saturation, and hydroxylation. These features likely enable the bacterium to fine-tune its response to fluctuating temperatures or other cold-related environmental stresses, contributing to resilience in the Arctic Ocean ecosystem. Furthermore, immunological assays demonstrate that both LPS and EPS produced by Polaribacter sp. SM1127 induce weak Toll-like receptor 4 activation and, in general, poorly stimulate the nuclear factor kappa-light-chain-enhancer of activated B cells pathway, compared to Escherichia coli LPS. These findings suggest their potential as immunomodulatory agents, like vaccine adjuvants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.